Orexigen Therapeutics - Driven by DTC
Contrave sales took a bit of a breather during Q317, which is considered part of the off-season for obesity drugs, with net US Contrave sales...
72 Views
Contrave outperforming
Orexigen’s re-launch of Contrave continues to be successful, with an 18% increase in prescriptions in the United States in Q217 compared to Q117....
61 Views
Contrave continues rebound
Orexigen’s consumer-focused re-launch of Contrave continues to be successful with a 39% increase in prescriptions in the United States in Q117...
118 Views
Contrave comeback
Orexigen’s decision to shift its US marketing focus from healthcare providers to consumers appears to be paying dividends as there has been a...
47 Views
No more insights